Tag Archives: Plus Therapeutics

Plus Therapeutics (PSTV) Gets a Buy Rating from Maxim Group

Maxim Group analyst Jason McCarthy assigned a Buy rating to Plus Therapeutics (PSTV – Research Report) yesterday and set a price target of $6.00. The company’s shares closed last Friday at $2.10. According to TipRanks.com, McCarthy is a 5-star analyst

Maxim Group Sticks to Their Buy Rating for Plus Therapeutics (PSTV)

In a report released yesterday, Jason McCarthy from Maxim Group reiterated a Buy rating on Plus Therapeutics (PSTV – Research Report), with a price target of $6.00. The company’s shares closed last Friday at $2.55. According to TipRanks.com, McCarthy is